BACKGROUND: Vascular smooth muscle cell (VSMC) proliferation is regulated by numerous hormones and humoral factors. Our previous study found that stimulation of D(1)-like dopamine receptors inhibited insulin receptor expression and function in VSMCs. We hypothesize that there is also an interaction between D(3) dopamine and insulin receptors, i.e., stimulation of the D(3) receptor inhibits insulin receptor expression and function. METHODS: Receptor expression was determined by immunoblotting, immunohistochemisty, and reverse transcriptase-PCR; VSMC proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-diphenyl-tetrazolium bromide (MTT) assay and cell number. RESULTS: Insulin receptor protein is increased in the aorta of D(3) receptor deficient mice. Stimulation of the D(3) receptor inhibited insulin receptor mRNA and protein expression and insulin-mediated VSMC proliferation, and increased protein kinase A (PKA) activity, insulin receptor phosphorylation, and degradation in immortalized aortic VSMCs (A10 cells). These effects were blocked by a PKA inhibitor, indicating that the D(3) receptor-mediated decrease in insulin receptor expression was related to a decrease in transcription/post-transcription and increased degradation, involving PKA signaling. CONCLUSIONS: D(3) receptor stimulation may be a target to reduce the adverse effect of insulin in hypertension by inhibition of insulin receptor expression and function in arterial VSMCs.
BACKGROUND: Vascular smooth muscle cell (VSMC) proliferation is regulated by numerous hormones and humoral factors. Our previous study found that stimulation of D(1)-like dopamine receptors inhibited insulin receptor expression and function in VSMCs. We hypothesize that there is also an interaction between D(3) dopamine and insulin receptors, i.e., stimulation of the D(3) receptor inhibits insulin receptor expression and function. METHODS: Receptor expression was determined by immunoblotting, immunohistochemisty, and reverse transcriptase-PCR; VSMC proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-diphenyl-tetrazolium bromide (MTT) assay and cell number. RESULTS:Insulin receptor protein is increased in the aorta of D(3) receptor deficient mice. Stimulation of the D(3) receptor inhibited insulin receptor mRNA and protein expression and insulin-mediated VSMC proliferation, and increased protein kinase A (PKA) activity, insulin receptor phosphorylation, and degradation in immortalized aortic VSMCs (A10 cells). These effects were blocked by a PKA inhibitor, indicating that the D(3) receptor-mediated decrease in insulin receptor expression was related to a decrease in transcription/post-transcription and increased degradation, involving PKA signaling. CONCLUSIONS: D(3) receptor stimulation may be a target to reduce the adverse effect of insulin in hypertension by inhibition of insulin receptor expression and function in arterial VSMCs.
Authors: Kristina M Fetalvero; Maureen Shyu; Athena P Nomikos; Yuh-Fang Chiu; Robert J Wagner; Richard J Powell; John Hwa; Kathleen A Martin Journal: Am J Physiol Heart Circ Physiol Date: 2006-01-06 Impact factor: 4.733
Authors: Xiaoyan Wang; Yingjin Luo; Crisanto S Escano; Zhiwei Yang; Laureano Asico; Hewang Li; John E Jones; Ines Armando; Quansheng Lu; David R Sibley; Gilbert M Eisner; Pedro A Jose Journal: Hypertension Date: 2010-04-19 Impact factor: 10.190
Authors: John-Andrews McQuade; Stephen C Benoit; Ming Xu; Stephen C Woods; Randy J Seeley Journal: Behav Brain Res Date: 2004-05-05 Impact factor: 3.332
Authors: Fengmin Li; Jian Yang; John Edward Jones; Van Anthony M Villar; Peiying Yu; Ines Armando; Robin A Felder; Pedro A Jose Journal: Endocrinology Date: 2015-03-31 Impact factor: 4.736
Authors: Andrew Kisling; Shannon Byrne; Rohan U Parekh; Deepthy Melit-Thomas; Lisandra E de Castro Brás; Robert M Lust; Stefan Clemens; Srinivas Sriramula; Laxmansa C Katwa Journal: Front Cardiovasc Med Date: 2021-10-11
Authors: Lisandra E de Castro Brás; Ryan S Schibalski; Daria V Ilatovskaya; Caitlin C O'Meara; Kristine Y DeLeon-Pennell Journal: Front Cardiovasc Med Date: 2022-04-18